NasdaqGM:ACIUBiotechs
AC Immune (ACIU) Loss Of CHF 15.9 Million Tests Bullish Profitability Narratives
AC Immune (NasdaqGM:ACIU) just posted third quarter FY 2025 revenue of CHF 0.9 million and a basic EPS loss of CHF 0.16, with quarterly net income excluding extra items at a loss of CHF 15.9 million. Over recent periods the company has seen revenue move between CHF 0.7 million and CHF 25.5 million per quarter, while EPS has ranged from a loss of around CHF 0.23 per share to a modest profit of CHF 0.06 per share, which underscores how sensitive results can be to revenue timing. For investors,...